


1/16



Fig. 1



09806568.073001


2/16

Fig. 2



09806568-0200

Fig. 3



09806568.073001

4/16

Fig. 4

kDa

94 —

67 —

43 —

30 —

20 —


14 —

Reduced Non-reduced

09806568

5/16


Fig. 5



09806568-073001


6/16

Fig. 6



7/16


Fig. 7



Reduced



Non-reduced

0 15 30 60 120min. 0 15 30 60 120min.





8/16

Fig. 8



9/16

Fig. 9




10/16

Fig. 10

A)

SDS-PAGE


		H		H	C		
	N	U	P	e	O	M	L
P	K	V	C	p	L	C	L
L	L	E	-	G	O	F	/
G	F	C	3	2	N	7	2



B)

Western blot with
anti-plasminogen antibody


		H		H	C		
	N	U	P	e	O	M	L
P	K	V	C	p	L	C	L
L	L	E	-	G	O	F	/
G	F	C	3	2	N	7	2




09806568-073001

Fig. 10 (continued)

c)
Cleavage patterns in the presence
of pepstatin A (inhibitor of aspartic enzyme)



D)
Cleavage patterns in the presence of E-64
(inhibitor of cysteine enzyme)



09806568.073004

12/16

Fig. 11






Fig. 12



Glu-Plasminogen Lys-Plasminogen



0 5 10 20 60 0 5 10 20 60
Reaction time (min.)

Fig. 13

kDa

94 —

67 —

43 —

30 —

20 —


14 —

Reduced Non-reduced

FOOEZD-B9590860


15/16

Fig. 14



09806568.073004

Fig. 15



T00E/0" 89590860